Breaking News
November 21, 2017 - Seven body organs you can live without
November 21, 2017 - Simple test could help predict best treatment for cystic fibrosis patients
November 21, 2017 - Diabetes patients’ immune system can regulate insulin production
November 21, 2017 - Simple mirror technique boosts the performance of diSPIM, study says
November 21, 2017 - FDA raids Florida stores that consumers use to buy drugs from Canada
November 21, 2017 - FDA Alert: Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory
November 21, 2017 - Exploring the genetics of glaucoma and retinal development
November 21, 2017 - Study finds sensors to detect biomarkers
November 21, 2017 - Researchers develop simple test to predict T2D remission after bariatric surgery
November 21, 2017 - Penn researchers find evidence of new malaria species in wild bonobos
November 21, 2017 - Review examines effectiveness of lipid-based products to treat dry eye disease
November 21, 2017 - Pioneering research project aims to develop better diagnostic tests for NAFLD
November 21, 2017 - The Best and Worst Ways to Say ‘I Love You’
November 21, 2017 - Even Partial Breast-Feeding for First Few Months Lowers SIDS Risk: MedlinePlus Health News
November 21, 2017 - Researchers identify protein that plays key role in diabetic blindness
November 21, 2017 - Sensors for identifying biomarkers could help detect myriad of diseases at early stages
November 21, 2017 - ‘Chemo brain’ may start as tumors form and develop, suggests study
November 21, 2017 - Scientists develop new method to study Creutzfeldt-Jakob disease in the lab
November 21, 2017 - Researchers identify previously unknown breast cell types
November 21, 2017 - Probing living cells with AFM
November 21, 2017 - Streamlined method for using CGM helps patients with diabetes maintain safe, stable glucose levels
November 21, 2017 - Even Advanced Breast Cancer Patients Gain From Exercise: MedlinePlus Health News
November 21, 2017 - Study in mice finds dietary levels of genistein may adversely affect female fertility
November 21, 2017 - Disordered eating has detrimental effects to long-term health of young adults, study finds
November 21, 2017 - Babies know more than we think they do find researchers
November 21, 2017 - New technique may reveal clues about role of centromeres in Down syndrome, other birth defects
November 21, 2017 - IUD May Lower Cervical Cancer Risk: MedlinePlus Health News
November 21, 2017 - U.S. preemie birth rates rise two years in a row
November 21, 2017 - Heart rate variability measured by electrocardiogram can help differentiate bipolar from major depression
November 21, 2017 - $10 million gift creates new center at Northwestern University to study effects of environment on genes
November 21, 2017 - Uncontrolled lung diseases could lead to costly A&E visits and hospital stays
November 21, 2017 - New study explores patients’ and family members’ views on overlapping surgeries
November 21, 2017 - KNAUER celebrates 55th anniversary and awards science prize
November 21, 2017 - Researchers find new way to boost cancer-destroying ability of T-cells
November 21, 2017 - Maintaining adequate vitamin D may help prevent onset of inflammatory diseases
November 21, 2017 - What NPs Can Do in the Opioid Crisis
November 21, 2017 - Gun Injuries Getting More Severe, Experts Say: MedlinePlus Health News
November 21, 2017 - That music playing in your head is a real conundrum for scientists
November 21, 2017 - Researcher awarded $1.5 million to study role of tumor necrosis factor in IBD
November 21, 2017 - Digital pills can help track opioid use patterns
November 21, 2017 - UZH leads Europe’s largest research on aging
November 21, 2017 - Experts endorse recommendations for restrictive blood transfusions
November 21, 2017 - New Hemophilia A Treatment, Hemlibra (Emicizumab-kxwh), Stems Bleeding Episodes
November 21, 2017 - Shining a light on the nervous system to thwart disease
November 21, 2017 - Use of Prostate Health Index cuts down need for uncomfortable biopsies
November 21, 2017 - Drugstore pain pills as effective as opioids in ER patients
November 21, 2017 - Experts explain why lead found in fidget spinners is no idle threat
November 21, 2017 - Over-the-counter decongestant found to be effective inhibitor of tumor stroma
November 21, 2017 - Anticholinergic Cognitive Burden Scale shows dose-response relationship with adverse outcomes
November 21, 2017 - Non-vitamin K antagonist oral anticoagulants linked to reduced kidney risks
November 21, 2017 - New technique holds promise to screen cancer cells for drug susceptibility
November 21, 2017 - AstraZeneca wins US approval for lymphoma drug
November 21, 2017 - Mother’s diet can protect nursing newborns against food allergies, research shows
November 21, 2017 - Cystic fibrosis patients have more good and bad bacteria in their lungs, study finds
November 21, 2017 - Patient-centered medical home model effective at improving chronic disease outcomes
November 21, 2017 - Enterovirus vaccine protects against virus-induced diabetes in mouse model
November 20, 2017 - First-of-its-kind study combines smoking cessation with personalized medicine
November 20, 2017 - FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 20, 2017 - Researchers produce the first draft cell atlas of the small intestine
November 20, 2017 - Study explores feasibility of mainstreaming genetic counseling for ovarian cancer
November 20, 2017 - AAP and The Obesity Society jointly address weight stigma in childhood obesity
November 20, 2017 - Researchers identify three specific molecules that accurately indicate pre-diabetes
November 20, 2017 - Study estimates health care costs, injuries, and deaths due to motorcycle accidents
November 20, 2017 - Face It: Drinking, Smoking Takes Toll on Looks
November 20, 2017 - Women have lower tolerance to alcohol following gastric sleeve surgery, study finds
November 20, 2017 - Salt, inflammation and hypertension
November 20, 2017 - Electrochemistry method provides easy access to important classes of compounds
November 20, 2017 - Cancer drugs may offer new way to control high blood pressure
November 20, 2017 - Small molecules in saliva may offer clues to diagnose and predict duration of concussions
November 20, 2017 - New poll demonstrates challenge of finding childcare options that meet parent’s safety criteria
November 20, 2017 - Canadians root for an underdog U.S. health policy idea
November 20, 2017 - KAIST researchers identify principles of gene network for colon tumorigenesis
November 20, 2017 - Pregnant mother in a coma wakes three months after delivery
November 20, 2017 - VTT researcher develops disposable optical test substrate for microbial detection
November 20, 2017 - Benzodiazepines linked to increased risk of death among Alzheimer’s disease patients
November 20, 2017 - Women are advised that sleeping on their side could reduce stillbirth risk
November 20, 2017 - The skinny on lipid immunology
November 20, 2017 - Study sheds light on changes in young people’s sexual practices
November 20, 2017 - Study highlights need for early identification, treatment of PTSD in cancer survivors
November 20, 2017 - FDA approves remote programming feature for Nucleus Cochlear Implant System via telemedicine
Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

image_pdfDownload PDFimage_print

dasotraline

Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

MARLBOROUGH, Mass.–(BUSINESS WIRE) November 10, 2017 –Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline, a novel dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) being evaluated for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults.

The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year. In total, approximately 2,500 people with ADHD were evaluated in these studies, and dasotraline was generally well tolerated.

“While there are a number of approved treatments for people living with ADHD, there remains a significant need for novel therapies that can address the needs of patients,” said Antony Loebel, M.D., Executive Vice President and Chief Medical Officer at Sunovion, Head of Global Clinical Development for Sumitomo Dainippon Pharma Group. “We are pleased that the FDA has accepted our New Drug Application for dasotraline and look forward to working closely with the Agency so that we can bring this important treatment option to people with ADHD.”

About Dasotraline

Dasotraline is a new chemical entity that acts as a dual dopamine and norepinephrine reuptake inhibitor (DNRI). It has an extended half-life (47-77 hours) that supports the potential for stable plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.

Dasotraline was discovered by Sunovion Pharmaceuticals Inc. and is currently in development to evaluate its use in treating attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). It has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD or BED.

About Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit hyperactivity disorder (ADHD) is a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning and development, as characterized by inattention (e.g., distractibility, forgetfulness) and/or hyperactivity and impulsivity (e.g., fidgeting, restlessness).1 Approximately 11 percent of children four to 17 years of age have been diagnosed with ADHD in the United States.2 Up to 60 percent of children with ADHD continue to experience symptoms into adulthood.3 It is estimated that 4.4 percent of adults between ages 18 and 44 years experience some symptoms and disabilities from ADHD in the U.S.4

In children, ADHD is associated with social rejection and reduced school performance.5 Children with a history of ADHD are ten times as likely to have difficulties with friendships and can have more frequent and severe injuries than peers without ADHD.6 In adults, symptoms reduce the quality of social or occupational functioning.5 Studies have shown that ADHD is associated with higher levels of unemployment, and those who are employed may experience workplace impairment, reduced productivity and behavioral issues.7 Adults with ADHD are also at increased risk of trauma, workplace injuries and traffic accidents, are more likely to be diagnosed with comorbid mental health conditions and have a higher incidence of separation and divorce.8,9,10

About Sunovion Pharmaceuticals Inc.

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Sunovion’s track record of discovery, development and/or commercialization of important therapies has included Utibron™ Neohaler ® (indacaterol/glycopyrrolate) Inhalation Powder, Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder, Brovana ® (arformoterol tartrate) Inhalation Solution, Latuda ® (lurasidone HCI) and Aptiom ® (eslicarbazepine acetate).

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan operating globally in major pharmaceutical markets, including Japan, the United States, China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about 6,500 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at www.ds-pharma.com.

LATUDA and SUNOVION are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.
APTIOM is a registered trademark of BIAL, used under license.
UTIBRON and SEEBRI are trademarks of Novartis AG, used under license.
NEOHALER is a registered trademark of Novartis AG, used under license.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
© 2017 Sunovion Pharmaceuticals Inc. All rights reserved.

References

1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association, 2013.
2 Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder (ADHD): Data and Statistics. [Internet]. Available from: http://www.cdc.gov/ncbddd/adhd/data.html. Accessed March 2017.
3 Targum SD. & Adler LA. Our Current Understanding of Adult ADHD. Innovations in Clinical Neuroscience. 2014; 11(11-12): 30–35.
4 National Resource Center on ADHD. General Prevalence of ADHD [Internet]. Available from: http://www.help4adhd.org/Understanding-ADHD/About-ADHD/Data-and-Statistics/General-Prevalence.aspx. Accessed March 2017.
5 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association, 2013.
6 Centers for Disease Control and Prevention. Attention-Deficit / Hyperactivity Disorder (ADHD): Other Concerns & Conditions. [Internet]. Available from: http://www.cdc.gov/ncbddd/adhd/conditions.html. Accessed March 2017.
7 Küpper, T, Haavik, J, Drexler, H, et al. The Negative Impact of Attention-Deficit/Hyperactivity Disorder on Occupational Health in Adults and Adolescents. International Archives of Occupational and Environmental Health. 2012: 85(8), 837-47.
8 Assessing Adults with ADHD and Comorbidities. Primary Care Companion to the Journal of Clinical Psychiatry. 2009;11(1): 25-43.
9 WebMD. Attention Deficit Hyperactivity Disorder in Adults [Internet]. Available from: http://www.webmd.com/add-adhd/guide/adhd-adults?page=2#2. Accessed March 2017.
10 Koblan, KS, Hopkins SC, Sarma, K, et al. Assessment of Human Abuse Potential of Dasotraline Compared to Methylphenidate and Placebo in Recreational Stimulant Users. Drug Alcohol Dependence. 2015; 159: 26-34.

Source: Sunovion Pharmaceuticals Inc.

Posted: November 2017

Related Articles

dasotraline FDA Approval History

Tagged with:

About author

Related Articles